TABLE 2

Incidence of HPV Types 6, 11, 16, and 18–Related CIN (Girls), EGLs, or Persistent Infection in Male and Female Subjects Vaccinated With the 4vHPV Vaccine in the Per-Protocol Efficacy Population

EVG Girls (N =614)CVG Girls (N = 262)
nNo. of CasesRate per 100 Person-yearsnNo. of CasesRate per 100 Person-years
HPV types 6,11,16 or 18 related persistent infection25730.39410.3
  HPV 6 related 254008900
  HPV 11 related 254008900
  HPV 16 related 25430.38710.3
  HPV 18 related 254009100
CIN227008300
EGL259009600
EVG Boys (N =565)CVG Boys (N = 220)
nNo. of CasesRate per 100 Person-yearsnNo. of CasesRate per 100 Person-years
HPV types 6,11,16 or 18 related persistent infection17750.66210.4
  HPV 6 related 17430.45610.4
  HPV 11 related 174005600
  HPV 16 related 17330.45900
  HPV 18 related 177006200
EGL179006200
  • CIN, cervical intraepithelial neoplasia; EGL, external genital lesion; F, female sex; M, male sex; N, number of subjects in the indicated group who received at least 1 dose of the 4vHPV vaccine; n, number of subjects who had at least 1 effectiveness follow-up visit. —, not applicable.